Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 8/20 | 0.38 |
| ▸ | MMP13 | P45452 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7607501 | 0.84 | MEN1 (0.57) | HPGDLMNAMEN1HTTKMT2A | |
| SCHEMBL5053071 | 0.80 | HPGD (0.47) | HPGDLMNAMEN1HTTKMT2A | |
| SCHEMBL5059732 | 0.78 | HPGD (0.51) | HPGDLMNAMEN1HTTKMT2A | |
| SCHEMBL5059737 | 0.78 | HPGD (0.51) | HPGDLMNAMEN1HTTKMT2A | |
| SCHEMBL5054539 | 0.74 | MMP1 (0.45) | HPGDMMP1MMP13ALDH1A1 | |
| SCHEMBL7607706 | 0.72 | KMT2A (0.50) | HPGDLMNAMEN1HTTKMT2A | |
| SCHEMBL7607419 | 0.72 | KMT2A (0.47) | HPGDLMNAMEN1HTTKMT2A | |
| SCHEMBL5053076 | 0.72 | MMP1 (0.46) | HPGDMMP1MMP13 | |
| SCHEMBL5051256 | 0.72 | HPGD (0.49) | HPGDLMNAMEN1HTTKMT2A | |
| SCHEMBL7609460 | 0.70 | MMP1 (0.39) | HPGDLMNAMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002514184-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |